Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Emergent Suspends COVID-19 Vaccine API Manufacturing As US FDA Inspects Bayview Plant

Apr 20 2021

• By Bowman Cox

Emergent BioSolutions — emergent vaccine drug substance quarantined, production suspended • Source: Alamy

Related Content

How BARDA Locked Up COVID-19 Vaccine Manufacturing Capacity For Operation Warp Speed

Jul 30 2020

BARDA Scales Up COVID-19 Vaccine Manufacturing Capacity With $628m For Emergent BioSolutions

Jun 01 2020

Related Companies

Emergent BioSolutions, Inc.

AstraZeneca PLC

Johnson & Johnson

Janssen Pharmaceuticals Inc.

Additional Topics

United States Coronavirus COVID-19 Vaccines Quality Compliance Manufacturing BioPharmaceutical

More from Vaccines

More from Pink Sheet

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.